In both pediatric and adult forms of glioma, glioblastoma, and myxoid glioneuronal tumors, somatic alterations of PDGFR have been observed, making imatinib a promising therapeutic candidate [44,88]. Here, PDGFRB is linked to central nervous system cancer.